Estelle Naumburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Estelle Naumburg has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Sven Cnattingius
Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden
4 shared publicationsAnders Ekbom
3 shared publicationsGustaf Tanghöj
Unit of Pediatrics, Department of Clinical Sciences, Umeå University, Umeå, Sweden
3 shared publicationsInge Axelsson
Östersund Hospital, Unit of Research, Education and Development, Östersund, Sweden
3 shared publicationsRino Bellocco
3 shared publications- Anders Rane
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 27 June 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (7) , 1-10
Glucose disturbances in very low birth weight infants nearing term age—results from the prospective LIGHT-study using continuous glucose monitoring
The purpose of the study is to assess the prevalence of glucose disturbances (dysglycemia) in very low birth weight (VLBW) infants at 36 weeks postmenstrual age (PMA) using a continuous glucose monitoring (CGM) system and to identify possible risk factors for these disturbances. A prospective observational cohort study (VLBW Infants—Glucose and Hormonal Profiles over Time; LIGHT) included 35 VLBW infants admitted to a single tertiary neonatal intensive care unit during 2016–2019. Perinatal data were registered prospectively. CGM registration was performed at 36 weeks PMA for a period of 48 h. Protracted hyperglycemia and hypoglycemia were defined as > 30 min with glucose concentrations > 8 mmol/L or < 2.6 mmol/L, respectively. A total of 19,907 measurements were retrieved and analyzed. Protracted dysglycemia was found in 68.6% of infants, with 51% of infants experiencing hyperglycemia (4.5% of registration time) and 40% experiencing hypoglycemia (1.2% of registration time). Male sex was associated with longer time spent in hyperglycemia. Insulin treatment prior to 36 weeks PMA was associated with longer time spent in hypoglycemia. CGM values correlated strongly with capillary glucose measurements, and no values fell within clinically dangerous ranges. Conclusion: Protracted dysglycemia is common in VLBW infants even at 36 weeks PMA. Identification of risk factors for dysglycemia might help delineate certain patients in need of careful monitoring of glucose concentrations even when nearing term age. CGM is a promising tool for glucose monitoring in the neonatal intensive care unit. What is Known? • Preterm infants are prone to glucose disturbances in the first weeks of life. • There is some evidence suggesting glucose disturbances are common in preterm infants nearing term age. • Glucose disturbances are associated with morbidity and mortality. What is New? • Continuous glucose registration data confirms subclinical glucose disturbances are common in preterm infants nearing term age. • Male sex and insulin treatment prior to 36 weeks postmenstrual age seem to be associated with glucose disturbances at 36 weeks postmenstrual age.
- 27 June 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (7) , 1-10
Open AccessGlucose disturbances in very low birth weight infants nearing term age—results from the prospective LIGHT-study using continuous glucose monitoring
The purpose of the study is to assess the prevalence of glucose disturbances (dysglycemia) in very low birth weight (VLBW) infants at 36 weeks postmenstrual age (PMA) using a continuous glucose monitoring (CGM) system and to identify possible risk factors for these disturbances. A prospective observational cohort study (VLBW Infants—Glucose and Hormonal Profiles over Time; LIGHT) included 35 VLBW infants admitted to a single tertiary neonatal intensive care unit during 2016–2019. Perinatal data were registered prospectively. CGM registration was performed at 36 weeks PMA for a period of 48 h. Protracted hyperglycemia and hypoglycemia were defined as > 30 min with glucose concentrations > 8 mmol/L or < 2.6 mmol/L, respectively. A total of 19,907 measurements were retrieved and analyzed. Protracted dysglycemia was found in 68.6% of infants, with 51% of infants experiencing hyperglycemia (4.5% of registration time) and 40% experiencing hypoglycemia (1.2% of registration time). Male sex was associated with longer time spent in hyperglycemia. Insulin treatment prior to 36 weeks PMA was associated with longer time spent in hypoglycemia. CGM values correlated strongly with capillary glucose measurements, and no values fell within clinically dangerous ranges. Conclusion: Protracted dysglycemia is common in VLBW infants even at 36 weeks PMA. Identification of risk factors for dysglycemia might help delineate certain patients in need of careful monitoring of glucose concentrations even when nearing term age. CGM is a promising tool for glucose monitoring in the neonatal intensive care unit. What is Known? • Preterm infants are prone to glucose disturbances in the first weeks of life. • There is some evidence suggesting glucose disturbances are common in preterm infants nearing term age. • Glucose disturbances are associated with morbidity and mortality. What is New? • Continuous glucose registration data confirms subclinical glucose disturbances are common in preterm infants nearing term age. • Male sex and insulin treatment prior to 36 weeks postmenstrual age seem to be associated with glucose disturbances at 36 weeks postmenstrual age.
- Open Access
- 1 August 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (12) , 2556-2563
Glucose disturbances in very low‐birthweight infants—Results from the prospective LIGHT study
Aim: To describe glucose homeostasis disturbances (dysglycaemia) in very low‐birthweight infants (10 mmol/L and hypoglycaemia <2.6 mmol/L were registered in 63% and 55% of the infants, respectively. Onset of dysglycaemia occurred almost exclusively in the first postnatal week. Hyperglycaemia followed 15% of corticosteroid doses given; all were preceded by pre‐existing hyperglycaemia. Pre‐existing hyperglycaemia was found in 66.7% of hyperglycaemic infants who received inotrope treatment. Upon commencement, 72.5% of antimicrobial treatments given were neither preceded nor followed by hyperglycaemia.Conclusion: Dysglycaemia was common in very low‐birthweight infants. Daily means of glucose concentrations seemed to follow a postmenstrual age‐dependent pattern, decreasing towards term age suggesting a postmenstrual age‐dependent developmental mechanism. The primary mechanism causing hyperglycaemia was independent of sepsis, and corticosteroid and inotrope treatments. No hypoglycaemia was registered during ongoing insulin treatment.
- 1 August 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (12) , 2556-2563
Open AccessGlucose disturbances in very low‐birthweight infants—Results from the prospective LIGHT study
Aim: To describe glucose homeostasis disturbances (dysglycaemia) in very low‐birthweight infants (10 mmol/L and hypoglycaemia <2.6 mmol/L were registered in 63% and 55% of the infants, respectively. Onset of dysglycaemia occurred almost exclusively in the first postnatal week. Hyperglycaemia followed 15% of corticosteroid doses given; all were preceded by pre‐existing hyperglycaemia. Pre‐existing hyperglycaemia was found in 66.7% of hyperglycaemic infants who received inotrope treatment. Upon commencement, 72.5% of antimicrobial treatments given were neither preceded nor followed by hyperglycaemia.Conclusion: Dysglycaemia was common in very low‐birthweight infants. Daily means of glucose concentrations seemed to follow a postmenstrual age‐dependent pattern, decreasing towards term age suggesting a postmenstrual age‐dependent developmental mechanism. The primary mechanism causing hyperglycaemia was independent of sepsis, and corticosteroid and inotrope treatments. No hypoglycaemia was registered during ongoing insulin treatment.
- Open Access
- 22 March 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (7) , 1621-1629
Adolescents on psychotropic treatment displayed longer corrected QT intervals than unmedicated controls when they rose rapidly from the supine position
Aim: Psychotropic medication can contribute to arrhythmia and identifying individuals at risk is crucial. This Swedish study compared the corrected QT (QTc) intervals of adolescents on psychotropic medication with unmedicated controls, when supine and after rising rapidly.Methods: The study was carried out at Östersund County Hospital in March 2022 and February to March 2023. It comprised 16 cases, aged 10–17 years and 28 controls. QTc intervals were measured with electrocardiography and calculated using Bazett's and Fridericia's formulas. Univariate and multiple linear regressions were used to assess differences in QTc intervals between the cases and controls and across sex, age and body mass index.Results: The mean QTc interval when supine, calculated with Bazett's formula, was longer for the adolescents on psychotropic medication than the controls (p = 0.046). The same was true for the mean QTc interval after rising rapidly from the supine position, calculated with both Bazett's formula (p = 0.009) and Fridericia's formula (p = 0.007). Mean QTc intervals varied by sex and age groups. Psychotropic medication prolonged QTc intervals, particularly in girls.Conclusion: Longer QTc intervals were found in adolescents on psychotropic medication, particularly after rising rapidly from the supine position.
- 22 March 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (7) , 1621-1629
Open AccessAdolescents on psychotropic treatment displayed longer corrected QT intervals than unmedicated controls when they rose rapidly from the supine position
Aim: Psychotropic medication can contribute to arrhythmia and identifying individuals at risk is crucial. This Swedish study compared the corrected QT (QTc) intervals of adolescents on psychotropic medication with unmedicated controls, when supine and after rising rapidly.Methods: The study was carried out at Östersund County Hospital in March 2022 and February to March 2023. It comprised 16 cases, aged 10–17 years and 28 controls. QTc intervals were measured with electrocardiography and calculated using Bazett's and Fridericia's formulas. Univariate and multiple linear regressions were used to assess differences in QTc intervals between the cases and controls and across sex, age and body mass index.Results: The mean QTc interval when supine, calculated with Bazett's formula, was longer for the adolescents on psychotropic medication than the controls (p = 0.046). The same was true for the mean QTc interval after rising rapidly from the supine position, calculated with both Bazett's formula (p = 0.009) and Fridericia's formula (p = 0.007). Mean QTc intervals varied by sex and age groups. Psychotropic medication prolonged QTc intervals, particularly in girls.Conclusion: Longer QTc intervals were found in adolescents on psychotropic medication, particularly after rising rapidly from the supine position.
- Open Access
- 27 February 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-6
Risk factors for isolated atrial septal defect secundum morbidity
Atrial septal defect secundum is a common type of congenital heart defect and even more common among children born premature. The aim of this study was to assess premature birth as a potential associated risk factors for cardiac morbidity in children with isolated ASD II. In this retrospective national registry-based case–control study all children born in Sweden between 2010 and 2015 with an isolated ASD II diagnosis were included. Association between premature birth and cardiac morbidity in children with isolated ASD II was assessed by different outcomes-models using conditional logistic regression and adjustments were made for confounding factors. Overall, 11% of children with an isolated ASD II received treatment for heart failure. Down syndrome was the only independent risk factors for associated with cardiac morbidity in children with ASD II (OR = 2.25 (95%CI 1.25–4.07). Preterm birth in children was not associated with an increased risk of ASD II cardiac morbidity.
- 27 February 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-6
Open AccessRisk factors for isolated atrial septal defect secundum morbidity
Atrial septal defect secundum is a common type of congenital heart defect and even more common among children born premature. The aim of this study was to assess premature birth as a potential associated risk factors for cardiac morbidity in children with isolated ASD II. In this retrospective national registry-based case–control study all children born in Sweden between 2010 and 2015 with an isolated ASD II diagnosis were included. Association between premature birth and cardiac morbidity in children with isolated ASD II was assessed by different outcomes-models using conditional logistic regression and adjustments were made for confounding factors. Overall, 11% of children with an isolated ASD II received treatment for heart failure. Down syndrome was the only independent risk factors for associated with cardiac morbidity in children with ASD II (OR = 2.25 (95%CI 1.25–4.07). Preterm birth in children was not associated with an increased risk of ASD II cardiac morbidity.
- Open Access
- 12 May 2023
- Published by Springer Nature in Research Square
Premature birth; a risk factor for atrial septal defect secundum morbidity? - a national case-control study
Atrial septal defect secundum is a common type of congenital heart defect and even more common among children born premature. Premature birth is linked to a biventricular systolic and diastolic myocardial dysfunction which in turn may increase morbidity in congenital heart shunt defects, such as ASD II. The aim of this study was to assess premature birth as a potential associated risk factors for cardiac morbidity in children with ASD II. In this retrospective national registry-based case-control study all children born in Sweden between 2010–2015 with an isolated ASD II diagnosis were included. Association between premature birth and cardiac morbidity in children with isolated ASD II was assessed by different outcomes-models using conditional logistic regression and adjustments were made for confounding factors. Down syndrome was the only independent risk factors for associated with cardiac morbidity in children with ASD II. Preterm birth in children was not associated with an increased risk of ASD II cardiac morbidity.
- 12 May 2023
- Published by Springer Nature in Research Square
Open AccessPremature birth; a risk factor for atrial septal defect secundum morbidity? - a national case-control study
Atrial septal defect secundum is a common type of congenital heart defect and even more common among children born premature. Premature birth is linked to a biventricular systolic and diastolic myocardial dysfunction which in turn may increase morbidity in congenital heart shunt defects, such as ASD II. The aim of this study was to assess premature birth as a potential associated risk factors for cardiac morbidity in children with ASD II. In this retrospective national registry-based case-control study all children born in Sweden between 2010–2015 with an isolated ASD II diagnosis were included. Association between premature birth and cardiac morbidity in children with isolated ASD II was assessed by different outcomes-models using conditional logistic regression and adjustments were made for confounding factors. Down syndrome was the only independent risk factors for associated with cardiac morbidity in children with ASD II. Preterm birth in children was not associated with an increased risk of ASD II cardiac morbidity.
- Open Access
- 16 December 2022
- Published by Wiley in Acta Paediatrica
- Vol. 112 (3) , 409-416
Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
Aim: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden.Methods: This was a descriptive national registry‐based study of children n = 64 (86.5%), and sildenafil was prescribed most frequently, n = 69 (93%). Bosentan, iloprost, macitentan and/or treprostinil were used mainly for combination therapies, n = 10 (13.5%). Patent ductus arteriosus or atrial septal defect were present in 29 (39%) and 25 (34%) children, respectively, and 20 (69%) versus 3 (12%) underwent closure. Cardiac catheterisation was performed in 19 (26%) patients. Median duration of therapy was 4.6 (1.9‐6.8, 95% CI) months. Mortality was 9%.Conclusion: Preterm children with bronchopulmonary dysplasia were prescribed pulmonary vasodilators, often without prior catheterisation. Sildenafil was most commonly used. Diagnostic tools, effects, and drug safety need further evaluation.
- 16 December 2022
- Published by Wiley in Acta Paediatrica
- Vol. 112 (3) , 409-416
Open AccessOutpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
Aim: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden.Methods: This was a descriptive national registry‐based study of children n = 64 (86.5%), and sildenafil was prescribed most frequently, n = 69 (93%). Bosentan, iloprost, macitentan and/or treprostinil were used mainly for combination therapies, n = 10 (13.5%). Patent ductus arteriosus or atrial septal defect were present in 29 (39%) and 25 (34%) children, respectively, and 20 (69%) versus 3 (12%) underwent closure. Cardiac catheterisation was performed in 19 (26%) patients. Median duration of therapy was 4.6 (1.9‐6.8, 95% CI) months. Mortality was 9%.Conclusion: Preterm children with bronchopulmonary dysplasia were prescribed pulmonary vasodilators, often without prior catheterisation. Sildenafil was most commonly used. Diagnostic tools, effects, and drug safety need further evaluation.
- Open Access
- 11 May 2021
- Published by Wiley in Health Science Reports
- Vol. 4 (2) , e288
Evidence of support used for drug treatments in pediatric cardiology
Background and aims: Clinical support systems are widely used in pediatric care. The aim of this study was to assess the support for drug treatments used at pediatric cardiac wards and intensive care units in Sweden.Methods: Drug information, such as type of drug, indication, dose, and route of administration, for all in‐hospital pediatric cardiac patients, was included in the study. Treatments were classified as either on‐label (based on product information) or off‐label. Support for off‐label treatment was stratified by the use of clinical support systems (the national database on drugs, local, or other clinical experience guidelines).Results: In all, 28 patients were included in the study. The total number of drug treatments was 233, encompassing 65 different drugs. Overall, 175 (75%) treatments were off‐label. A majority of off‐label drug treatments were supported by other sources of information shared by experts. A total of 7% of the drug treatments were used without support.Conclusion: Off‐label drug treatment is still common in Swedish pediatric cardiac care. However, the majority of treatments were supported by the experience shared in clinical support systems.Key Points: Seventy‐five percent of all prescriptions in pediatric cardiology care were off‐label. A majority of patients received three or more drug treatments off‐label. Use of clinical support systems and guidelines was common, but in 7% of all drug treatments, no support was found for the chosen treatment.
- 11 May 2021
- Published by Wiley in Health Science Reports
- Vol. 4 (2) , e288
Open AccessEvidence of support used for drug treatments in pediatric cardiology
Background and aims: Clinical support systems are widely used in pediatric care. The aim of this study was to assess the support for drug treatments used at pediatric cardiac wards and intensive care units in Sweden.Methods: Drug information, such as type of drug, indication, dose, and route of administration, for all in‐hospital pediatric cardiac patients, was included in the study. Treatments were classified as either on‐label (based on product information) or off‐label. Support for off‐label treatment was stratified by the use of clinical support systems (the national database on drugs, local, or other clinical experience guidelines).Results: In all, 28 patients were included in the study. The total number of drug treatments was 233, encompassing 65 different drugs. Overall, 175 (75%) treatments were off‐label. A majority of off‐label drug treatments were supported by other sources of information shared by experts. A total of 7% of the drug treatments were used without support.Conclusion: Off‐label drug treatment is still common in Swedish pediatric cardiac care. However, the majority of treatments were supported by the experience shared in clinical support systems.Key Points: Seventy‐five percent of all prescriptions in pediatric cardiology care were off‐label. A majority of patients received three or more drug treatments off‐label. Use of clinical support systems and guidelines was common, but in 7% of all drug treatments, no support was found for the chosen treatment.
- Open Access
- 1 December 2020
- Published by Wiley in Acta Paediatrica
- Vol. 109 (12) , 2740-2747
Improved infrastructure and support needed for paediatric clinical trials in Sweden
Aim There is a lack of authorised medicines for paediatric patients and improved drug development is necessary. The aim of this study was to evaluate the need for infrastructure and support for paediatric clinical trials in Sweden. Methods A web-based survey was sent to doctors and nurses involved in the care of neonates, children and adolescents assessing the current situation and future needs for paediatric clinical trials in Sweden. Questions regarding premises, competence, organisation, support for paediatric clinical trials and Good Clinical Practice Training were addressed. Results In total, 137 individuals responded to the survey (109 doctors and 28 nurses). Overall, 61% of the respondents had previous experience of paediatric clinical trials. Some respondents had access to trial units, but only 34% had used the trial unit for support. Half of the responders were interested in recurrent paediatric Good Clinical Practice training. Doctors responded that clinical work often had to be prioritised and emphasised the need for research time. Conclusion This study clearly shows the commitment for clinical trials among doctors and nurses involved in paediatric care in Sweden, but also that administrative, logistic and economic support in a sustainable setting and an expanded national collaboration are needed.
- 1 December 2020
- Published by Wiley in Acta Paediatrica
- Vol. 109 (12) , 2740-2747
Open AccessImproved infrastructure and support needed for paediatric clinical trials in Sweden
Aim There is a lack of authorised medicines for paediatric patients and improved drug development is necessary. The aim of this study was to evaluate the need for infrastructure and support for paediatric clinical trials in Sweden. Methods A web-based survey was sent to doctors and nurses involved in the care of neonates, children and adolescents assessing the current situation and future needs for paediatric clinical trials in Sweden. Questions regarding premises, competence, organisation, support for paediatric clinical trials and Good Clinical Practice Training were addressed. Results In total, 137 individuals responded to the survey (109 doctors and 28 nurses). Overall, 61% of the respondents had previous experience of paediatric clinical trials. Some respondents had access to trial units, but only 34% had used the trial unit for support. Half of the responders were interested in recurrent paediatric Good Clinical Practice training. Doctors responded that clinical work often had to be prioritised and emphasised the need for research time. Conclusion This study clearly shows the commitment for clinical trials among doctors and nurses involved in paediatric care in Sweden, but also that administrative, logistic and economic support in a sustainable setting and an expanded national collaboration are needed.
- Open Access
- 1 October 2020
- Published by Springer Nature in Journal of Congenital Cardiology
- Vol. 4 (1)
Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
Background: Infants with congenital heart disease (CHD) have an increased risk of morbidity and mortality during a respiratory syncytial virus (RSV) infection. The aim of this study was to estimate the cost-effectiveness of palivizumab as RSV-prophylaxis among infants with CHD, including the effect of delayed heart surgery and asthma.Methods: A simulation model with data from the literature and health care authorities including costs and utilities was developed to estimate costs and health effects over a lifetime for a cohort of CHD infants receiving palivizumab compared to no RSV-prophylaxis.Results: The prophylaxis treatment incurred a cost of 3664 EUR per treated infant. However, due to cost-savings from primarily avoiding hospitalizations (5145 EUR/treated infant) and avoiding heart complications due to delayed heart surgery (2082 EUR/treated infant), the RSV-prophylaxis treatment resulted in a total cost-saving of 3833 EUR per treated infant. At the same time, the prophylaxis-treated cohort accumulated more life-years and higher quality of life than the non-prophylaxis cohort.Conclusion: This study confirms that RSV-prophylaxis in severe CHD infants less than one year of age is cost beneficial. Avoiding delayed heart surgeries is an important benefit of prophylaxis and should be taken into consideration.
- 1 October 2020
- Published by Springer Nature in Journal of Congenital Cardiology
- Vol. 4 (1)
Open AccessCost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
Background: Infants with congenital heart disease (CHD) have an increased risk of morbidity and mortality during a respiratory syncytial virus (RSV) infection. The aim of this study was to estimate the cost-effectiveness of palivizumab as RSV-prophylaxis among infants with CHD, including the effect of delayed heart surgery and asthma.Methods: A simulation model with data from the literature and health care authorities including costs and utilities was developed to estimate costs and health effects over a lifetime for a cohort of CHD infants receiving palivizumab compared to no RSV-prophylaxis.Results: The prophylaxis treatment incurred a cost of 3664 EUR per treated infant. However, due to cost-savings from primarily avoiding hospitalizations (5145 EUR/treated infant) and avoiding heart complications due to delayed heart surgery (2082 EUR/treated infant), the RSV-prophylaxis treatment resulted in a total cost-saving of 3833 EUR per treated infant. At the same time, the prophylaxis-treated cohort accumulated more life-years and higher quality of life than the non-prophylaxis cohort.Conclusion: This study confirms that RSV-prophylaxis in severe CHD infants less than one year of age is cost beneficial. Avoiding delayed heart surgeries is an important benefit of prophylaxis and should be taken into consideration.